China LAMEA Oncology/Anti-cancer drugs Market Research Report 2018

Table of Contents

China LAMEA Oncology/Anti-cancer drugs Market Research Report 2018

1 LAMEA Oncology/Anti-cancer drugs Overview

• 1.1 Product Overview and Scope of LAMEA Oncology/Anti-cancer drugs
• 1.2 Classification of LAMEA Oncology/Anti-cancer drugs by Product Category
  • 1.2.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) Comparison by Type (2013-2025)
  • 1.2.2 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) Market Share by Type in 2017
  • 1.2.3 Blood Cancer
  • 1.2.4 Breast Cancer
  • 1.2.5 Gastrointestinal Cancer
  • 1.2.6 Prostate Cancer
  • 1.2.7 Others
• 1.3 China LAMEA Oncology/Anti-cancer drugs Market by Application/End Users
  • 1.3.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Market Share Comparison by Applications (2013-2025)
  • 1.3.2 Chemotherapy
  • 1.3.3 Targeted Therapy
  • 1.3.4 Immunotherapy (Biologic Therapy)
  • 1.3.5 Hormonal Therapy
  • 1.3.6 Others
• 1.4 China LAMEA Oncology/Anti-cancer drugs Market by Region
  • 1.4.1 China LAMEA Oncology/Anti-cancer drugs Market Size (Million USD) Comparison by Region (2013-2025)
  • 1.4.2 South China LAMEA Oncology/Anti-cancer drugs Status and Prospect (2013-2025)
  • 1.4.3 East China LAMEA Oncology/Anti-cancer drugs Status and Prospect (2013-2025)
  • 1.4.4 Southwest China LAMEA Oncology/Anti-cancer drugs Status and Prospect (2013-2025)
  • 1.4.5 Northeast China LAMEA Oncology/Anti-cancer drugs Status and Prospect (2013-2025)
  • 1.4.6 North China LAMEA Oncology/Anti-cancer drugs Status and Prospect (2013-2025)
  • 1.4.7 Central China LAMEA Oncology/Anti-cancer drugs Status and Prospect (2013-2025)
• 1.5 China Market Size (Sales and Revenue) of LAMEA Oncology/Anti-cancer drugs (2013-2025)
  • 1.5.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Growth Rate (%)(2013-2025)
  • 1.5.2 China LAMEA Oncology/Anti-cancer drugs Revenue (Million USD) and Growth Rate (%)(2013-2025)

2 China LAMEA Oncology/Anti-cancer drugs Market Competition by Players/Manufacturers

• 2.1 China LAMEA Oncology/Anti-cancer drugs Sales and Market Share of Key Players/Manufacturers (2013-2018)
• 2.2 China LAMEA Oncology/Anti-cancer drugs Revenue and Share by Players/Manufacturers (2013-2018)
• 2.3 China LAMEA Oncology/Anti-cancer drugs Average Price (USD/Unit) by Players/Manufacturers (2013-2018)
• 2.4 China LAMEA Oncology/Anti-cancer drugs Market Competitive Situation and Trends
  • 2.4.1 China LAMEA Oncology/Anti-cancer drugs Market Concentration Rate
  • 2.4.2 China LAMEA Oncology/Anti-cancer drugs Market Share of Top 3 and Top 5 Players/Manufacturers
  • 2.4.3 Mergers & Acquisitions, Expansion in China Market
• 2.5 China Players/Manufacturers LAMEA Oncology/Anti-cancer drugs Manufacturing Base Distribution, Sales Area, Product Types

3 China LAMEA Oncology/Anti-cancer drugs Sales and Revenue by Region (2013-2018)

• 3.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Market Share by Region (2013-2018)
• 3.2 China LAMEA Oncology/Anti-cancer drugs Revenue (Million USD) and Market Share by Region (2013-2018)
• 3.3 China LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) by Regions (2013-2018)

4 China LAMEA Oncology/Anti-cancer drugs Sales and Revenue by Type/ Product Category (2013-2018)

• 4.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Market Share by Type/ Product Category (2013-2018)
• 4.2 China LAMEA Oncology/Anti-cancer drugs Revenue (Million USD) and Market Share by Type (2013-2018)
• 4.3 China LAMEA Oncology/Anti-cancer drugs Price (USD/Unit) by Type (2013-2018)
• 4.4 China LAMEA Oncology/Anti-cancer drugs Sales Growth Rate (%) by Type (2013-2018)

5 China LAMEA Oncology/Anti-cancer drugs Sales by Application (2013-2018)

• 5.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) and Market Share by Application (2013-2018)
• 5.2 China LAMEA Oncology/Anti-cancer drugs Sales Growth Rate (%) by Application (2013-2018)
• 5.3 Market Drivers and Opportunities

6 China LAMEA Oncology/Anti-cancer drugs Players/Suppliers Profiles and Sales Data

• 6.1 Roche
  • 6.1.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.1.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.1.2.1 Product A
    • 6.1.2.2 Product B
  • 6.1.3 Roche LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.1.4 Main Business/Business Overview
• 6.2 Novartis
  • 6.2.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.2.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.2.2.1 Product A
    • 6.2.2.2 Product B
  • 6.2.3 Novartis LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.2.4 Main Business/Business Overview
• 6.3 Celgene
  • 6.3.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.3.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.3.2.1 Product A
    • 6.3.2.2 Product B
  • 6.3.3 Celgene LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.3.4 Main Business/Business Overview
• 6.4 Amgen
  • 6.4.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.4.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.4.2.1 Product A
    • 6.4.2.2 Product B
  • 6.4.3 Amgen LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.4.4 Main Business/Business Overview
• 6.5 Johnson & Johnson
  • 6.5.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.5.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.5.2.1 Product A
    • 6.5.2.2 Product B
  • 6.5.3 Johnson & Johnson LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.5.4 Main Business/Business Overview
• 6.6 GlaxoSmithKline
  • 6.6.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.6.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.6.2.1 Product A
    • 6.6.2.2 Product B
  • 6.6.3 GlaxoSmithKline LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.6.4 Main Business/Business Overview
• 6.7 Eli lilly & Co
  • 6.7.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.7.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.7.2.1 Product A
    • 6.7.2.2 Product B
  • 6.7.3 Eli lilly & Co LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.7.4 Main Business/Business Overview
• 6.8 Pfizer
  • 6.8.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.8.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.8.2.1 Product A
    • 6.8.2.2 Product B
  • 6.8.3 Pfizer LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.8.4 Main Business/Business Overview
• 6.9 Merck & Co.
  • 6.9.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.9.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.9.2.1 Product A
    • 6.9.2.2 Product B
  • 6.9.3 Merck & Co. LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.9.4 Main Business/Business Overview
• 6.10 Sanofi
  • 6.10.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.10.2 LAMEA Oncology/Anti-cancer drugs Product Category, Application and Specification
    • 6.10.2.1 Product A
    • 6.10.2.2 Product B
  • 6.10.3 Sanofi LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%)(2013-2018)
  • 6.10.4 Main Business/Business Overview

7 LAMEA Oncology/Anti-cancer drugs Manufacturing Cost Analysis

• 7.1 LAMEA Oncology/Anti-cancer drugs Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Price Trend of Key Raw Materials
  • 7.1.3 Key Suppliers of Raw Materials
  • 7.1.4 Market Concentration Rate of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
  • 7.2.1 Raw Materials
  • 7.2.2 Labor Cost
  • 7.2.3 Manufacturing Expenses
• 7.3 Manufacturing Process Analysis of LAMEA Oncology/Anti-cancer drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

• 8.1 LAMEA Oncology/Anti-cancer drugs Industrial Chain Analysis
• 8.2 Upstream Raw Materials Sourcing
• 8.3 Raw Materials Sources of LAMEA Oncology/Anti-cancer drugs Major Manufacturers in 2017
• 8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
  • 9.1.3 Marketing Channel Development Trend
• 9.2 Market Positioning
  • 9.2.1 Pricing Strategy
  • 9.2.2 Brand Strategy
  • 9.2.3 Target Client
• 9.3 Distributors/Traders List

10 Market Effect Factors Analysis

• 10.1 Technology Progress/Risk
  • 10.1.1 Substitutes Threat
  • 10.1.2 Technology Progress in Related Industry
• 10.2 Consumer Needs/Customer Preference Change
• 10.3 Economic/Political Environmental Change

11 China LAMEA Oncology/Anti-cancer drugs Market Size (Sales and Revenue) Forecast (2018-2025)

• 11.1 China LAMEA Oncology/Anti-cancer drugs Sales (K Units), Revenue (Million USD) Forecast (2018-2025)
• 11.2 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) Forecast by Type (2018-2025)
• 11.3 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) Forecast by Application (2018-2025)
• 11.4 China LAMEA Oncology/Anti-cancer drugs Sales (K Units) Forecast by Region (2018-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Disclaimer